Subscribe to our Newsletters !!
There is one fact about life on Earth we cannot es
In biological research, especially in areas such a
The Nobel Prize in Physiology or Medicine awarded
In today’s rapidly evolving bioprocessing landsc
By the end of 2025, the pharma, laboratory, and an
Tofu has been a favorite food for vegetarians and
Dear Readers, Welcome to the latest issue of The Magazine
Alembic Pharmaceuticals Limited (Alembic) today announced that its wholly owned subsidiary, Aleor Dermaceuticals Limited (Aleor) has received final approval from the US Food & Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) for Diclofenac Sodium Topical Gel, 3%.The approved ANDA is therapeutically equivalent to the reference listed drug product (RLD) Solaraze Topical Gel, 3%, of Fougera Pharmaceuticals Inc. (Fougera). Diclofenac Sodium Topical Gel, 3% is indicated for the topical treatment of actinic keratoses. Sun avoidance is indicated during therapy.
Diclofenac Sodium Topical Gel, 3% has an estimated market size of US$10 million for twelve months ending Mar., 2022 according to IQVIA.
Alembic has received a cumulative total of 169 ANDA approvals (145 final approvals and 24 tentative approvals) from USFDA.
